Search hospitals > Michigan > Troy

Michigan Institute of Urology-Town Center

Claim this profile
Troy, Michigan 48084
Global Leader in Prostate Cancer
Global Leader in Bladder Cancer
Conducts research for Lung Cancer
Conducts research for Breast Cancer
Conducts research for Breast cancer
96 reported clinical trials
11 medical researchers
Photo of Michigan Institute of Urology-Town Center in TroyPhoto of Michigan Institute of Urology-Town Center in TroyPhoto of Michigan Institute of Urology-Town Center in Troy

Summary

Michigan Institute of Urology-Town Center is a medical facility located in Troy, Michigan. This center is recognized for care of Prostate Cancer, Bladder Cancer, Lung Cancer, Breast Cancer, Breast cancer and other specialties. Michigan Institute of Urology-Town Center is involved with conducting 96 clinical trials across 132 conditions. There are 11 research doctors associated with this hospital, such as Dana Zakalik, Andrew A. Muskovitz, Faisal Musa, and Joseph M. Anderson.

Area of expertise

1Prostate Cancer
Global Leader
Michigan Institute of Urology-Town Center has run 28 trials for Prostate Cancer. Some of their research focus areas include:
Stage IV
PSA
Gleason Score
2Bladder Cancer
Global Leader
Michigan Institute of Urology-Town Center has run 18 trials for Bladder Cancer.

Top PIs

Clinical Trials running at Michigan Institute of Urology-Town Center

Lung Cancer
Breast Cancer
Esophageal cancer
Bladder Cancer
Prostate Cancer
Breast cancer
Ovarian Cancer
Stomach Cancer
Colorectal Cancer
Gastric cancer
Image of trial facility.

Immunotherapy + Chemotherapy

for Non-Small Cell Lung Cancer

This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting2 awards Phase 327 criteria
Image of trial facility.

Crizotinib

for Non-Small Cell Lung Cancer

This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Image of trial facility.

Biomarker Screening Test

for Lung Cancer

This study is part of the development of a non-invasive lung cancer screening test which aim to identify early-stage lung cancer in patients at high risk for lung cancer.
Recruiting1 award N/A3 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Michigan Institute of Urology-Town Center?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security